385 related articles for article (PubMed ID: 29177732)
1. DNA Topoisomerases as Targets for Antibacterial Agents.
Hiasa H
Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
[TBL] [Abstract][Full Text] [Related]
2. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
[TBL] [Abstract][Full Text] [Related]
3. Targeting bacterial topoisomerases: how to counter mechanisms of resistance.
Tse-Dinh YC
Future Med Chem; 2016 Jun; 8(10):1085-100. PubMed ID: 27285067
[TBL] [Abstract][Full Text] [Related]
4. New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
Badshah SL; Ullah A
Eur J Med Chem; 2018 May; 152():393-400. PubMed ID: 29751233
[TBL] [Abstract][Full Text] [Related]
5. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
[TBL] [Abstract][Full Text] [Related]
7. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
Kokot M; Anderluh M; Hrast M; Minovski N
J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
[TBL] [Abstract][Full Text] [Related]
8. Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
Ho SY; Wang W; Ng FM; Wong YX; Poh ZY; Tan SWE; Ang SH; Liew SS; Joyner Wong YS; Tan Y; Poulsen A; Pendharkar V; Sangthongpitag K; Manchester J; Basarab G; Hill J; Keller TH; Cherian J
Eur J Med Chem; 2018 Sep; 157():610-621. PubMed ID: 30125722
[TBL] [Abstract][Full Text] [Related]
9. Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.
Tomašić T; Mašič LP
Curr Top Med Chem; 2014; 14(1):130-51. PubMed ID: 24236722
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
[TBL] [Abstract][Full Text] [Related]
11. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
[TBL] [Abstract][Full Text] [Related]
12. ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents.
Durcik M; Tomašič T; Zidar N; Zega A; Kikelj D; Mašič LP; Ilaš J
Expert Opin Ther Pat; 2019 Mar; 29(3):171-180. PubMed ID: 30686070
[TBL] [Abstract][Full Text] [Related]
13. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
Metwally NH; Abdallah SO; Mohsen MMA
Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
[TBL] [Abstract][Full Text] [Related]
14. Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs).
Kolarič A; Anderluh M; Minovski N
J Med Chem; 2020 Jun; 63(11):5664-5674. PubMed ID: 32027491
[TBL] [Abstract][Full Text] [Related]
15. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
[TBL] [Abstract][Full Text] [Related]
17. Identification of secondary metabolites from Crescentia cujete as promising antibacterial therapeutics targeting type 2A topoisomerases through molecular dynamics simulation.
Aribisala JO; Abdulsalam RA; Dweba Y; Madonsela K; Sabiu S
Comput Biol Med; 2022 Jun; 145():105432. PubMed ID: 35344868
[TBL] [Abstract][Full Text] [Related]
18. Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.
Magarò G; Prati F; Garofalo B; Corso G; Furlotti G; Apicella C; Mangano G; D'Atanasio N; Robinson D; Di Giorgio FP; Ombrato R
J Med Chem; 2019 Aug; 62(16):7445-7472. PubMed ID: 31276392
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.
Azam MA; Thathan J; Jubie S
Bioorg Chem; 2015 Oct; 62():41-63. PubMed ID: 26232660
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
